Arterial hypertension is one of the greatest threats to public health. In this article, you will find complete guidelines, pharmacotherapy, prevention strategies, and current innovations, all clearly described by specialists. Learn how to effectively diagnose, treat, and prevent hypertension to protect yourself and your loved ones.
Discover effective methods of treating arterial hypertension – the latest guidelines, modern pharmacotherapies, prevention, and the best specialist advice.
Table of Contents
- What is arterial hypertension and why does it threaten your health?
- New guidelines and classifications in the treatment of hypertension 2024
- Combined drugs and pharmacotherapy – what you should know
- Modern innovations – new active substances and therapies
- Lifestyle changes and prevention in hypertension
- When to see a doctor and key tests
What is arterial hypertension and why does it threaten your health?
Arterial hypertension (hypertension) is a chronic cardiovascular disorder in which blood pressure values in the arteries remain persistently above normal, regardless of momentary stress, physical exertion, or other transient factors. In clinical practice, it is usually diagnosed in adults when, in repeated office measurements, the systolic (upper) blood pressure is at least 140 mmHg and/or the diastolic (lower) pressure is at least 90 mmHg. However, home measurements and 24-hour blood pressure monitoring (ABPM) are increasingly important, with slightly lower threshold values—this matters because many people have so-called “white coat” hypertension or, conversely, masked hypertension, i.e., normal readings in the office but elevated during daily life. Understanding exactly what hypertension is also requires knowing what is considered normal blood pressure: optimal values are around 120/80 mmHg, but some fluctuations are physiological and depend on age, sex, time of day, or body load. The root of hypertension is a disturbance in the complex mechanism that regulates blood pressure, involving the heart (pumping blood), blood vessels (their diameter and elasticity), kidneys (regulating blood volume and sodium-water balance), and the hormonal and nervous systems. If any of these elements function incorrectly or are chronically overloaded—e.g., due to obesity, sedentary lifestyle, excessive salt intake, chronic stress, or genetic factors—blood pressure starts to rise and eventually becomes persistently elevated. Medicine distinguishes between primary (essential) hypertension, which accounts for about 90–95% of all cases and results from a complex interplay of genes and lifestyle, and secondary hypertension, which results from another disease, such as kidney disorders, renal artery stenosis, hormonal imbalances (thyroid hyperactivity, adrenal pheochromocytoma, primary hyperaldosteronism), obstructive sleep apnea or the effects of certain drugs (e.g., glucocorticoids, NSAIDs, oral contraceptives). The key problem with hypertension is its insidious, covert course—most sufferers do not experience any specific symptoms for a long time, and if they do, such as headaches, ringing in the ears, palpitations, dizziness, concentration difficulties, or chronic fatigue, these are easily blamed on exhaustion, age, or stress. For this reason, hypertension is called the “silent killer”: it does not provide clear warning signs, yet silently damages blood vessels and internal organs every day. Persistent, uncontrolled elevation of blood pressure forces the heart to work harder to overcome increased resistance in the vessels, which leads to left ventricular hypertrophy, its gradual weakening, the development of heart failure, and rhythm disturbances. The arterial walls become thicker and stiffer, atherosclerosis progresses, and the lumen narrows, hindering blood flow and promoting clot formation. At the same time, high pressure damages small vessels in the brain, kidneys, and retina, which can result in vascular dementia, chronic kidney disease, and vision disturbances.
Hypertension threatens health primarily because it significantly increases the risk of the most serious cardiovascular diseases, which are the main cause of death in developed countries. If untreated or poorly controlled, it leads to heart attacks, strokes, aortic aneurysm, advanced heart failure, or sudden cardiac death—and what’s more, it is often one of the most important modifiable risk factors in these conditions, alongside smoking, hypercholesterolemia, diabetes, and abdominal obesity. Prolonged overloading of blood vessels can cause microdamage, formation of atherosclerotic plaque, blood flow disorders to organs, and, consequently, ischemia. In practice, this means that high blood pressure ‘works’ for years to eventually trigger an acute incident—for example, moderately elevated values over a decade increase the likelihood that with an additional factor, such as severe stress, dehydration, infection, or exertion, a coronary vessel will be blocked by a clot and a heart attack will develop. Strokes—both ischemic and hemorrhagic—are equally dangerous, with hypertension being the single most important risk factor; by damaging the walls of small cerebral vessels, it promotes their rupture or blockage by clots. High blood pressure also affects cognitive functions: chronic hypertension is associated with a higher risk of memory impairment, decreased intellectual performance, and dementia, including Alzheimer’s disease, since it disrupts microcirculation in the brain and accelerates neurodegenerative processes. The impact of hypertension on the kidneys is also noteworthy—their role is crucial in regulating blood pressure, but they are also particularly sensitive to its elevation. Chronically elevated pressure damages glomeruli, leading to progressive loss of filtration, proteinuria, and in severe cases, end-stage renal failure requiring dialysis or transplantation. Hypertension also accelerates the development of hypertensive retinopathy—damage to the retinal vessels—which can result in decreased vision quality or even blindness. These risks are compounded by the fact that many people are unaware of the disease: according to epidemiological studies, a significant portion of patients with elevated pressure remain undiagnosed, and among those diagnosed, some do not follow recommended therapy or discontinue treatment once symptoms subside, believing that “everything has returned to normal.” Meanwhile, hypertension is a chronic disease requiring systematic monitoring and long-term control, even when values are normal thanks to treatment—otherwise, damage to blood vessels and organs will progress. The combination of its asymptomatic, chronic nature, very high prevalence, and serious, often irreversible complications makes hypertension one of modern medicine and public health’s greatest challenges, with early detection and effective treatment being crucial to reducing heart attacks, strokes, and premature deaths.
New guidelines and classifications in hypertension treatment 2024
In 2024, international and European cardiology societies maintain a similar definition of arterial hypertension (≥140/90 mmHg in office measurements), but place even greater emphasis on early detection of elevated blood pressure and comprehensive assessment of total cardiovascular risk. Blood pressure classifications usually include: optimal (<120/80 mmHg), normal (120–129/80–84 mmHg), high-normal (130–139/85–89 mmHg), and three grades of hypertension (I: 140–159/90–99 mmHg, II: 160–179/100–109 mmHg, III: ≥180/≥110 mmHg). A novelty in the current guidelines is an even greater role for measurements outside the physician’s office: home measurements (HBPM – home blood pressure monitoring) and 24-hour monitoring (ABPM – ambulatory blood pressure monitoring). It is increasingly stressed that without such tests, the so-called white coat hypertension (high values only in the office) or masked hypertension (normal in-office, elevated at home) may be missed, both of which carry similar complication risks as classic hypertension. The updated recommendations also propose more precise diagnostic thresholds depending on measurement method: for home measurements, hypertension is considered as average values ≥135/85 mmHg, and in ABPM – ≥130/80 mmHg for the 24-hour mean. In 2024, the decision to start drug therapy depends not only on blood pressure level itself but also on the patient’s overall cardiovascular risk, assessed using scales like SCORE2/SCORE2-OP. In people without additional risk factors, pharmacotherapy usually begins when blood pressure is persistently ≥140/90 mmHg, but in patients at high or very high risk (e.g., after a heart attack, with diabetes, chronic kidney disease, or left ventricular hypertrophy), medications are often introduced already at borderline or high-normal levels if lifestyle modification does not bring rapid improvements. The 2024 guidelines shift focus from “treating hypertension” to “reducing global risk” – thus, besides blood pressure pharmacotherapy, aggressive treatment of lipid disorders (statins, ezetimibe, PCSK9 inhibitors), glycemic control, and strict restriction of tobacco and alcohol consumption are strongly recommended. Modern classifications also include specific hypertension phenotypes, such as resistant hypertension (persisting above target despite three drugs at optimal doses, including a diuretic), secondary hypertension (related to kidney disease, renal artery stenosis, obstructive sleep apnea, or hormone-secreting tumors), and isolated systolic hypertension, typical for older people with stiffened vessels. For each of these variants, more detailed diagnostic algorithms have been established for 2024, indicating when to refer patients to specialty centers, suspect a hormonal cause (e.g., primary hyperaldosteronism), and which additional diagnostic (imaging and lab) tests are most clinically and economically worthwhile.
The current 2024 guidelines for hypertension treatment also highlight that therapeutic targets should be tailored to age, comorbidities, and treatment tolerance. In most adults, the aim is a systolic pressure between 120–130 mmHg and diastolic 70–79 mmHg, provided the patient tolerates therapy well, without experiencing dizziness or symptoms of organ ischemia. In those aged above 65–70, a slightly higher lower threshold (130–139 mmHg systolic) is often recommended to reduce the risk of falls, fainting, and impaired cerebral perfusion. In 2024, early implementation of combination therapy has become a priority – instead of starting with a single drug and gradually adding more, immediate use of a two-substance single-pill preparation (e.g., ACE inhibitor or sartan + calcium antagonist or thiazide/thiazide-like diuretic) is recommended, which facilitates compliance and enables faster risk factor target achievement. In patients with very high baseline blood pressure, very high cardiovascular risk, or resistant hypertension, guidelines promote triple-drug regimes in a single tablet (so-called single-pill combinations), reducing the number of daily doses. Newer recommendations also put more emphasis on personalizing therapy taking into account age, gender, body weight, kidney and liver function, and potential interactions with other medications (e.g., those for diabetes, thyroid disease, depression, or rheumatic diseases). The use of digital tools for monitoring hypertension—mobile apps, smart blood pressure monitors transmitting data to doctors, and telemedicine consultations—is becoming increasingly popular, facilitating rapid therapy adjustment. In 2024, the importance of intensive but safe lifestyle modification was confirmed—weight loss, sodium-reduced diet (to about 5 g/day), increased intake of vegetables, fruits, and whole grains (DASH diet or Mediterranean diet models, see diets), regular aerobic physical activity (at least 150 minutes of moderate exercise weekly), and stress reduction techniques such as breathing exercises or mindfulness. Modern guidelines clearly state that non-pharmacological interventions are not just an “addition” to medication but an equally important pillar of therapy, reducing the number and doses of drugs, and often delaying the need for pharmacotherapy in those with borderline hypertension. At the same time, modern—but still under evaluation—interventional procedures are appearing, such as renal denervation (RDN), recommended only at specialized centers and for patients with documented, truly resistant hypertension unresponsive to conservative treatment. All these changes in the guidelines and classifications for 2024 share a common goal: to identify at-risk individuals more precisely, reach target blood pressure values faster, and at the same time minimize side effects and improve patient quality and length of life.
Combined drugs and pharmacotherapy – what you should know?
Hypertension pharmacotherapy has evolved greatly in recent years—from single pills taken several times a day to modern combination drugs containing two or even three different active agents in a single tablet. The main drug groups for treating hypertension remain: angiotensin-converting enzyme inhibitors (ACEI), sartans (ARB), calcium channel blockers (CCB), thiazide and thiazide-like diuretics (e.g., indapamide), and beta-blockers. The latest guidelines promote the “starting in combination” strategy, i.e., initiating treatment for most patients with two drugs in one tablet instead of gradually adding monotherapies. This is because hypertension is multifactorial—various pathophysiological mechanisms (e.g., activation of the RAA system, increased sodium retention, vasoconstriction) require simultaneous pharmacological interventions at several levels. From the patient’s perspective, the key advantage of combination drugs is convenience—fewer pills per day mean better adherence to treatment and less risk of missed doses. It is well known that even the best treatment plan loses efficacy if medications are not taken regularly. Combination drugs also reduce blood pressure fluctuations during the day, as they usually contain substances with prolonged action and can be taken once daily at a fixed time. The most common combinations are: ACEI or ARB with a thiazide/thiazide-like diuretic (e.g., perindopril + indapamide, valsartan + hydrochlorothiazide) or ACEI/ARB with a calcium antagonist (e.g., ramipril + amlodipine, telmisartan + amlodipine). Such combinations utilize a synergistic effect—one drug dilates vessels, another removes excess sodium and water, a third may further protect the heart or kidneys, enabling effective and safe blood pressure reduction at lower doses of each ingredient and thus reducing the risk of side effects. Importantly, modern combinations in a single tablet are designed to reduce common adverse effects simultaneously, e.g., adding a diuretic to a calcium channel blocker can alleviate limb edema, and combining ACEI with a diuretic reduces potassium loss.
In practice, the choice of a specific combination drug depends on the patient profile, age, comorbidities, and tolerance to active substances. Different combos are chosen for a young person with isolated hypertension versus a patient with diabetes, heart failure, or chronic kidney disease. For example, in diabetic patients, ACEI or sartans are preferred (kidney protection), often combined with a thiazide-like diuretic or calcium antagonist, whereas in coronary artery disease, beta-blockers play a key role, often within triple-drug regimens. Increasingly, cardiologists and primary care doctors use three-component preparations (e.g., ACEI/ARB + CCB + diuretic), allowing for target blood pressure achievement in more advanced or “resistant” hypertension, where monotherapy or two-drug regimes are insufficient. It should be noted that the use of combination drugs requires close cooperation with a doctor—splitting tablets, dosage changes, or discontinuing therapy on your own may lead to sudden pressure spikes, dizziness, fainting, or worsening of comorbidities. Regular lab tests are essential: creatinine and eGFR (kidney function), electrolytes (sodium, potassium), and with diuretics—uric acid and glucose. The doctor may then adjust the composition or doses based on results to prevent complications such as hyperkalemia, heart rhythm disorders, or dehydration. Contemporary hypertension pharmacotherapy is further supported by digital solutions—home blood pressure monitors with app data recording, telemedicine, remote monitoring, medication reminders. These systems help specialists assess whether blood pressure stays within therapeutic targets (usually <130/80 mmHg for most, with alternatives for the elderly), and whether therapy changes are needed. Although modern combination drugs significantly facilitate hypertension control, they do not replace healthy lifestyle—salt reduction, weight loss, physical activity, moderating alcohol, and quitting smoking. Optimal effects are achieved only with lifestyle changes coupled with well-chosen, guideline-based pharmacotherapy under regular medical supervision.
Modern innovations – new active substances and therapies
The development of hypertension therapy in recent years goes far beyond classic groups like ACE inhibitors, sartans, or beta-blockers. Innovative active substances and advanced technologies are playing an increasingly important role, aimed not only at more effectively lowering blood pressure but also at improving cardiovascular prognosis, organ protection, and increasing treatment safety. One of the most promising trends are neprilysin inhibitors combined with angiotensin receptor antagonists (so-called ARNI). These drugs, initially used mainly for heart failure, are increasingly considered for patients with difficult-to-control hypertension and coexisting heart failure because they combine vasodilatory effects (via increased levels of natriuretic peptides) with blockade of the renin–angiotensin–aldosterone system. Research shows not only more effective pressure reduction, but also decreased risk of heart failure hospitalization, which is especially important for older long-term hypertensive patients. In parallel, new-generation mineralocorticoid receptor antagonists (e.g., finerenone) are being tested, which, unlike classic spironolactone derivatives, are more selective, reducing risk of side effects like gynecomastia or hormonal disorders. In clinical practice, they are gaining importance, especially for those with hypertension and chronic kidney disease or diabetes, where they also exert nephroprotective benefits. Another step forward includes drugs modulating the sympathetic system at new targets, e.g., imidazoline receptor agonists or drugs targeting specific adrenergic receptor subtypes in kidneys and vessels. This allows pressure reduction with less impact on heart rate and less risk of weakness, somnolence, or metabolic disturbances often seen with older drugs. Clinical trials also introduce ultra-long-acting preparations (>24 hours) enabling even more stable blood pressure control during the day and minimizing early morning pressure surges, a major risk factor for stroke and heart attack.
Beyond classic oral pharmacotherapy, the field of interventional and biologic therapies targeting specific hypertension mechanisms is progressing rapidly. The most talked-about recent innovation is percutaneous renal artery denervation—a minimally invasive vascular procedure involving the destruction of sympathetic nerve fibers surrounding the renal arteries using radiofrequency or ultrasound energy. In some patients with treatment-resistant hypertension, even despite combination therapy, denervation results in sustained pressure reduction by several mmHg, which can significantly lower cardiovascular complications. While not intended for all, new guidelines now consider this option for high/very-high risk patients whose pressure remains uncontrolled despite optimal pharmacotherapy. Simultaneously, other invasive methods are being analyzed, such as renal artery stenting for specific cases of hemodynamically important stenosis, or experimental carotid baroreceptor modulation techniques, which via constant electrical stimulation “reset” pressure regulation systems to lower levels. The most advanced innovations also include biological therapies, such as monoclonal antibodies targeting elements of the renin–angiotensin system or sodium-handling hormones. Though still in research, their goal is to provide a long-lasting, stable hypotensive effect with a single subcutaneous injection every few weeks or months, which could be a breakthrough for those struggling with daily tablets. Alongside these big innovations, a whole range of digital tools is developing—smart blood pressure monitors transmitting results to a doctor, medication reminder apps, and AI algorithms predicting sudden pressure increases based on past measurements, sleep, activity, and other parameters. Together with new substances and procedures, these solutions create an increasingly personalized model of hypertension care, where therapy is tailored to blood pressure values, comorbidities, lifestyle, the patient’s preferences, and individual risk profile.
Lifestyle changes and prevention in hypertension
Changing lifestyle is the foundation of hypertension treatment and is recommended both for those already diagnosed and those at increased cardiovascular risk. Contemporary guidelines emphasize that even the best pharmacotherapy cannot fully compensate for unhealthy habits. A key prevention element is dietary modification. It is recommended to follow a dietary model close to the DASH or Mediterranean diet, rich in vegetables, fruits, whole grains, legumes, nuts, and low-fat dairy. Reducing salt intake below 5 g/day (about one flat teaspoon, including “hidden” salt in bread, cured meats, and processed foods) can lower systolic pressure by several mmHg. At the same time, limiting saturated and trans fats and replacing them with unsaturated fats in olive oil, rapeseed oil, fatty sea fish, or avocado is advised. Also important are adequate intakes of potassium, magnesium, and calcium, which stabilize cardiovascular function—their natural sources are vegetables, fruit, nuts, and seeds. Avoiding excessive sweetening of drinks and products is also key, as obesity and insulin resistance are strongly correlated with hypertension development. Alcohol drinkers should limit consumption to safe levels: men, no more than 20–30 g of pure alcohol per day (e.g., 500 ml beer or 200 ml wine), women, 10–20 g; however, it is advised that alcohol-free days outnumber drinking days each week. Completely quitting smoking is a very important preventive aspect, as nicotine causes sudden (though short-lived) pressure spikes, and tobacco smoke accelerates atherosclerosis, further straining the heart and vessels. Equally important as diet is weight control—reducing body weight by 5–10% in those overweight or obese leads to clear pressure reduction and lower demand for antihypertensive drugs. In practice, this means aiming for a BMI of 20–25 kg/m² and reducing waist circumference to under 80 cm in women and 94 cm in men. Implementation of changes should be gradual and realistic, so that new habits become a permanent part of daily life, instead of a short-term “miracle diet.”
The second pillar of non-pharmacological hypertension treatment is regular physical activity, tailored to age, fitness, and comorbidities. At least 150–300 minutes of moderate activity per week (e.g., brisk walking, cycling, Nordic walking, swimming) or 75–150 minutes of vigorous activity, supplemented by 2–3 strength training sessions for major muscle groups, is recommended. Even just 30 minutes of walking daily, most days per week, can lower systolic blood pressure by 5–8 mmHg. However, very intense, sudden strains should be avoided, especially in the untrained or those with advanced heart disease; in such cases, activity plans should be discussed with a doctor. Sleep hygiene also plays a significant role—chronic insomnia and obstructive sleep apnea are independent hypertension risk factors. Keeping fixed sleep hours, avoiding screen exposure just before bed, and sleep apnea screening in snorers or those excessively sleepy during the day can bring measurable pressure control benefits. Stress management cannot be overlooked: persistent stress activates the sympathetic system and HPA axis, raising cortisol and adrenaline levels, which leads to sustained pressure increases. Relaxation techniques such as breathing exercises, mindfulness meditation, yoga, or regular outdoor walks lower nervous tension. Digital tools are also helpful for prevention—blood pressure monitor apps, pedometers, and smartwatches that remind users to move, record measurements, and allow doctors to assess blood pressure control at home. Special attention should be given to primary prevention in young people with a family history—regular measurements, periodic tests, education on healthy living, and avoiding stimulants can significantly delay or even prevent hypertension. Effective prevention requires coordinated action at several levels: individual (informed patient), family (joint healthy food and activity choices), and societal (access to healthy foods, sports infrastructure, and reliable health education), resulting in not only better pressure control but also improvement in overall life quality and expectancy.
When to see a doctor and key tests
Arterial hypertension can be asymptomatic for a long time, so it’s worth seeing a doctor not only when “something happens” but also for preventive reasons. An adult with no diagnosis of hypertension or other significant cardiovascular diseases should check their blood pressure at least every 1–2 years, and from age 40, preferably once a year. An urgent medical consultation should be prompted by repeated values above 140/90 mmHg measured at rest at home on different days of the week. Especially concerning are values over 160/100 mmHg, particularly if accompanied by symptoms such as severe headache, palpitations, vision problems, dizziness, chest pain, breathlessness, or episodes of sudden weakness on one side of the body or speech disturbances. In such cases, do not delay the visit, and with very high values (e.g., ≥180/110 mmHg) accompanied by symptoms suggesting organ damage (chest pain, rest dyspnea, consciousness disorders, limb numbness, sudden visual loss), immediate emergency care or calling an ambulance is necessary—this may indicate a hypertensive crisis. It’s also wise to visit your primary care doctor if a single office reading is elevated, but home values are normal—this may be white coat hypertension or the beginning of sustained hypertension requiring further diagnostics.
Certain groups should be particularly alert and seek consultation earlier, even with borderline pressure values (130–139/85–89 mmHg). This applies to those with obesity, diabetes, chronic kidney disease, high cholesterol, smokers, and those with a family history of premature heart attacks or strokes. Women planning pregnancy or pregnant should consult a doctor already at the planning stage because some antihypertensive drugs are contraindicated during pregnancy, and untreated hypertension increases risks both for mother and child. During the visit, the doctor will not only measure blood pressure but also order a set of tests to assess total cardiovascular risk and possible organ damage. Key tests include basic bloodwork: lipid profile (total cholesterol, LDL, HDL, triglycerides), fasting glucose, glycated hemoglobin (HbA1c) for diabetes or prediabetes screening, and renal function (creatinine, eGFR, electrolyte panel—mainly sodium and potassium). Urinalysis is also very important (urine test) to detect protein or microscopic blood, which may indicate hypertensive kidney damage. Resting ECG is standard, useful to assess whether persistent elevated pressure has caused left ventricular hypertrophy or rhythm disturbances. Depending on age, symptoms, and comorbidities, the doctor may order a heart echocardiogram, renal artery ultrasound, abdominal ultrasound, chest X-ray, or eye fundus exam to assess hypertensive vascular changes in the retina.
24-hour blood pressure monitor (ABPM) and structured home readings (HBPM) have growing importance in diagnosis. ABPM involves wearing a special device for 24 hours, recording pressure every 15–30 minutes by day and 30–60 minutes by night—thus, it’s possible to assess pressure’s natural behavior, whether it drops properly at night, and detect masked hypertension (normal office readings but elevated outside) or white coat hypertension. Home self-measurements—two readings morning and evening, over several days—are a crucial complement to evaluation and often essential for diagnosis and therapy modification. In some patients, especially young people with very high pressures, or when hypertension appears suddenly and is severe, the doctor may suspect secondary hypertension and order specialized hormonal tests (e.g., aldosterone, renin, cortisol, thyroid hormones, plasma or daily urinary catecholamines) and imaging for adrenal glands, kidneys, or pituitary. Remember, early doctor visits and basic testing enable not just hypertension diagnosis, but detection of other often “silent” diseases like diabetes, chronic kidney disease, or atherosclerosis. Regular check-ups and lab monitoring are then essential to assess treatment effectiveness, medication safety, and make dose adjustments, which in practice translates to a lower risk of future cardiovascular complications.
Summary
Arterial hypertension is one of the most common chronic diseases, which if untreated leads to serious cardiovascular conditions. Thanks to new guidelines, innovative therapies, and combination drugs, treatment efficacy has significantly increased. The keys are regular pressure monitoring, lifestyle adaptation, and collaboration with your doctor. Early diagnosis and prevention enable not only better disease control but also prevention of its dangerous complications. Take care of your health and make informed decisions when treating hypertension.
